What to expect from Tuesday’s CDC meeting about BioNTech and Pfizer’s COVID-19 shots for young children

The U.S. is preparing to roll out BioNTech SE BNTX, +2.20% and Pfizer Inc.’s PFE, +3.41% COVID-19 vaccine to children between the ages of 5 and 11 years old later this week.

There are about 28 million children in the U.S. in this age group who have not yet qualified for a COVID-19 shot. The U.S. has secured enough doses of the vaccine developed by these companies to cover this group of children, the White House said Monday.